<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40226">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01952223</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1202</org_study_id>
    <secondary_id>2012-000566-38</secondary_id>
    <nct_id>NCT01952223</nct_id>
  </id_info>
  <brief_title>A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse</brief_title>
  <acronym>PEACE2</acronym>
  <official_title>A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic
      radiotherapy in combination with ADT-radiotherapy on clinical progression-free survival in
      patients with high-risk localized prostate cancer (with a stringent selection of patients
      with at least 2 high-risk features), in a 2 by 2 factorial trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomized via the TENALEA web site process that insure
      centralization of the randomization.

      Randomization will be performed according a 1:1:1:1 ratio. The randomization will be
      stratified (by minimization) according to the number of risk factors (2 vs.3), disease
      extent (pN- vs. pN+ vs. pNx) and the site.

      The minimization will be defined with a similar weight for all 3 stratification factors and
      a probability of assigning the treatment that minimize the imbalance equal to 80%.

      The main analysis of PFS will be event driven (&gt;247 events). It will likely be performed
      when the median follow-up is approximately 6 years, i.e. 4 years after the inclusion of the
      last patient (assuming an accrual of 4 years).

      A long-term analysis (allowing for robust PFS and OS data) will also be performed when the
      follow-up is approximately 10 years. Its exact timing will be discussed with the steering
      committee and the IDMC.

      An interim analysis of the primary endpoint is planned. This interim analysis will be
      performed at a 0.001 level (Peto) after 50% of the events i.e. 125 have occurred.

      For each comparison (CT comparison and pelvic RT comparison) the two PFS curves will be
      compared using the adjusted logrank test (bilateral test): adjusted logrank on pelvic RT for
      the CT comparison and on CT for the pelvic RT comparison. A multivariate analysis using the
      Cox model will also be used.

      An Independent Data Monitoring Committee (IDMC) composed of international experts (at least
      2 physicians and 1 statistician) will be selected.

      For safety purpose, the IDMC will meet after the inclusion of 20 patients (and then again
      after accrual of 50 patients) in the cabazitaxel and pelvic radiotherapy arm, to assess
      tolerance, (i.e. after the inclusion of approximately 80 and then 200 patients in the
      trial). Depending on the results of this feasibility phase and of any new relevant clinical
      results in such a population, the remaining patients (n=848) will be enrolled.

      During this second phase, the IDMC will then meet every two years approximately during
      accrual to carefully assess accrual rate and toxicity and examine the efficacy interim
      analysis results in the light of the results of similar trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>prostate-specific antigen response at 3 months</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical progression-free survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metastases-free survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local relapse-free survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer-specific survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of treatment on serum testosterone</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term toxicity</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive biomarkers of treatment efficacy</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1048</enrollment>
  <condition>Adenocarcinoma of Prostate</condition>
  <condition>Progression of Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ADT + pelvic RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT for a total duration of 3 years i.e.LHRH agonist or LHRH antagonist +/-Peripheral anti-androgen
Pelvic RT (by IMRT or IGRT protocol):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT Cabazitaxel: 4 CT cycles
Prostate-only RT (IMRT or IGRT):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT Cabazitaxel: 4 CT cycles
Pelvic RT (IMRT or IGRT):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + prostate radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen
Prostate-only RT (IMRt or IGRT):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Cabazitaxel administered at 25mg/m2 as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles</description>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <other_name>jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic radiotherapy</intervention_name>
    <description>Prostate+pelvic RT (2 Gy fractions, 5 times per week):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
    <arm_group_label>ADT + pelvic RT</arm_group_label>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>prostate radiotherapy</intervention_name>
    <description>Prostate-only RT (2 Gy fractions, 5 times per week):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_label>ADT + prostate radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Any T histologically confirmed adenocarcinoma of the prostate 2) No clinically or
             radiologically suspected metastases, including no enlarged pelvic lymph nodes (&gt; 1 cm
             in small diameter) 3) Gleason score ≥7 4) Meets at least 2 of the following criteria
             for high-risk:

          -  Gleason score ≥ 8

          -  T3 or T4 disease  (T3 defined by MRI is acceptable)

          -  Prostate-specific antigen equal or greater than 20 ng/mL 5) No prior treatment for
             prostate cancer except lymph node dissection (patients with pN- and pN+ disease can
             be accrued).

             6) 18 years ≤ Age≤ 75 years 7) ECOG 0-1 performance status 8) Expected life
             expectancy of more than 10 years 9) Absolute neutrophil count ≥ 1.5 x 109/L 10)
             Platelets ≥ 100 x 109/L 11) Hb ≥ 9.0 g/dL 12) Hepatic function: serum bilirubin ≤ 1
             ULN; AST and ALT ≤ 2.5 x ULN 13) Renal function (creatinine clearance using the
             CKD-EPI formula (Chronic Kidney Disease Epidemiology group) ≥ 60 mL/min).

             14) Potentially reproductive patients must agree to use an effective contraceptive
             method while on treatment and for 6 months after the final dose of investigational
             product.

             15) Patients must be affiliated to a Social Security System or should fulfill the
             country legislation for clinical trials.

             16) Patients who have received the information sheet and signed the informed consent
             form.

             17) Patients must be willing and able to comply with scheduled visits, treatment
             plan, laboratory tests and other study procedures

        Exclusion Criteria:

          -  1) Patients with other known concurrent severe and/or uncontrolled medical disease
             which could compromise participation in the study, such as:

               1. infection,

               2. cardiac disease such as uncontrolled hypertension, congestive cardiac failure,
                  ventricular arrhythmias, active ischemic heart disease, myocardial infarction
                  within one year, LVEF &gt; grade 2,

               3. uncontrolled diabetes mellitus,

               4. current active hepatic or biliary disease (with exception of subjects with
                  Gilbert's syndrome, asymptomatic gallstones, stable chronic liver disease per
                  investigator assessment),

               5. renal disease,

               6. active GI tract ulceration, malabsorption syndrome, disease significantly
                  affecting gastrointestinal function, or resection of the stomach or small bowel.
                  Subjects with active, uncontrolled ulcerative colitis are also excluded,

               7. known severely impaired lung function (spirometry and DLCO 70% or less of normal
                  and O2 saturation of 88% or less at rest on room air).

                  2) Other prior malignancy within the last 5 years, except basal cell skin cancer
                  3) Physical or psychological condition that would preclude study compliance 4)
                  Hypersensitivity to cabazitaxel (hypersensitivity reaction ≥grade 3), to other
                  taxanes, or to any excipients of the formulation including polysorbate 80 5)
                  Patients with significantly altered mental status prohibiting the understanding
                  of the study or with psychological, familial, sociological or geographical
                  condition potentially hampering compliance with the study protocol and follow-up
                  schedule; those conditions should be discussed with the patient before
                  registration in the trial.

                  6) Patients who received any other investigational drugs within the 30 days
                  prior to the start of cabazitaxel.

                  7) Previous pelvic irradiation that make prostatic irradiation impossible 8)
                  Severe GI disorders precluding pelvic irradiation 9) Patients already included
                  in another therapeutic trial involving an experimental drug 10) Individual
                  deprived of liberty or placed under the authority of a tutor. 11) Concomitant
                  prohibited treatment. Concurrent or planned treatment with strong inhibitors or
                  strong inducers of cytochrome P450 3A4/5 (see Appendix 6). A one week wash-out
                  period is necessary for patients who are already on these treatments
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle BOMPAS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO-René Gauducheau - St Herblain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tan Dat NGUYEN, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jean Godinot - Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilhem ROUBAUD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié - Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc FERRERO, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne - Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-michel VANNETZEL, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Hartmann - neuilly sur Seine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe BEUZEBOC, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aline GUILLOT, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth -ST Priest en Jarez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude EL KOURI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Catherine de Sienne - Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank PRIOU, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE - La Roche sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aude FLECHON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE LEON BERARD - lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor LATORZEFF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris-Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean BERDAH, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ste Marguerite - Hyères</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane CULINE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Louis - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie ABADIE-LACOURTOISIE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO - Paul Papin - Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe FOURNERET, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de Chambéry - Chambéry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain GRANDGIRARD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de Mulhouse - mulhouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia BURBAN-PROVOST, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine de Radiologie - St Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loïc MOUREY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius REGAUD - Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain RUFFION, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier Lyon Sud - Pierre Bénite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine THIERY-VUILLEMIN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Jean Minoz - Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre CLAVERE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges - Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique BECKENDORF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de cancérologie de Lorraine, Vandoeuvre les Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel HABIBIAN</last_name>
    <phone>+33(0)176647807</phone>
    <email>m-habibian@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Fizazi, MD, PhD</last_name>
      <phone>33-1-4211-6264</phone>
      <email>fizazi@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinome</keyword>
  <keyword>prostate</keyword>
  <keyword>relapse</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <keyword>Cabazitaxel</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
